InnoCan Pharma:
Auf dem EPIDIOLEX®-Pfad zum Milliarden-Unternehmen.
Anzeige

PLx Pharma WKN: A2DMUN ISIN: US72942A1079 Kürzel: 1D5A

Kurs zur PLX PHARMA Aktie
2,26 EUR
+3,79 %+0,08
26. May, 19:02:14 Uhr, Lang & Schwarz
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
Summer.76
Summer.76, 13. Mai 15:33
https://www.globenewswire.com/news-release/2022/05/13/2442870/37097/en/PLx-Pharma-Inc-Reports-First-Quarter-2022-Results-and-Provides-Business-Update.html
Summer.76
Summer.76, 11. Mär 16:12
https://www.biospace.com/article/releases/plx-pharma-inc-reports-fourth-quarter-and-full-year-2021-results-and-provides-business-update/?s=110 PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Momentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules • Total Net Sales of $8.2 Million in Last Five Months of 2021 • Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter 2021 • Key Performance Measures Are Positive and Trending Higher; Company on Track and Well-Positioned to Grow Sales Substantially in 2022 • GAAP Net Loss of ($0.73) Per Diluted Share in Fourth Quarter 2021; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.73) • Cash & Cash Equivalent Balance of $69.4 Million at Year-End 2021
nionus
nionus, 07.02.2022 7:25
https://youtu.be/O_OCb5owR7g TV Werbespot der aktuell in den USA läuft.
nionus
nionus, 07.12.2021 19:03
https://seekingalpha.com/news/3777793-plx-pharma-gains-after-raymond-james-upgraded-on-valuation
nionus
nionus, 15.11.2021 19:28
https://zolmax.com/investing/plx-pharma-inc-nasdaqplxp-shares-purchased-by-vanguard-group-inc/6508739.html
Summer.76
Summer.76, 12.11.2021 13:15
PLx Pharma EPS beats by $0.09, beats on revenue https://seekingalpha.com/news/3769940-plx-pharma-eps-beats-0_09-beats-on-revenue?utm_source=webull.com&utm_medium=referral • PLx Pharma (NASDAQ:PLXP): Q3 Non-GAAP EPS of -$0.37 beats by $0.09; GAAP EPS of -$0.80 misses by $0.34. • Revenue of $6.6M beats by $2.5M.
Summer.76
Summer.76, 12.11.2021 13:12
PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update https://finance.yahoo.com/news/plx-pharma-inc-reports-third-115000911.html -- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites -- -- Reported net revenue of $6.6 million in third quarter 2021 reflecting initial sales of VAZALORE -- -- Third quarter 2021 net loss was ($0.80) per share and adjusted non-GAAP net loss per share of ($0.37) -- -- Early feedback received from consumers and healthcare professionals is very positive -–
Summer.76
Summer.76, 04.11.2021 17:12
PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules https://finance.yahoo.com/news/plx-pharma-inc-announces-scientific-135000021.html -- VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition -- -- VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent with VAZALORE 325 mg -- ...
nionus
nionus, 01.11.2021 19:40
https://www.analystratings.com/articles/jmp-securities-remains-a-buy-on-plx-pharma-plxp/
Summer.76
Summer.76, 29.10.2021 15:11
PLx Pharma Inc. Provides VAZALORE Launch Update https://www.globenewswire.com/news-release/2021/10/29/2323515/0/en/PLx-Pharma-Inc-Provides-VAZALORE-Launch-Update.html -- Supplied VAZALORE to 30,000+ stores nationwide and e-commerce sites -- -- Launch in line with expectations and exceptionally positive feedback from consumers and healthcare professionals received -- -- Third quarter 2021 earnings and business update conference call scheduled for November 12th -- ...
Kommentare
1 PLX PHARMA Hauptdiskussion
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Frankfurt 2,22 2,30 1653544867 08:01 2,15 EUR
Berlin 2,22 2,30 1653544978 08:02 2,15 EUR
Düsseldorf 2,21 2,31 1653555670 11:01 1,99 EUR
Stuttgart 2,20 2,32 1653544880 08:01 2,09 EUR
Nasdaq 2,41 2,43 1653583437 18:43 38.577 Stk 2,43 USD
AMEX 1653508920 25. May 100 Stk 1,83 USD
Tradegate 2,22 2,31 1653510439 25. May 2,18 EUR
Lang & Schwarz 2,22 2,31 1653584534 19:02 2,26 EUR
London 1652451609 13. May 2,35 USD
ges. 38.677 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
205,2 Mio.
Anzahl der Aktien
27,5 Mio.
Grundlegende Daten zur PLX PHARMA Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -
BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2022 börsennews.de

Daten und Kurse:

TTMzero RealTime

SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.